BTK Inhibitor Use and Social Determinants in CLL / SLL [ASH 2023] Chronic Lymphocytic Leukemia 2 Mins Read175 David J. Andorsky, MD, an Associate Chair for US Oncology Hematology Research and a member of the Rocky Mountain Cancer’s…
BTK Degrader BGB-16673:Phase 1 Results in B-Cell Malignancies [ASH 2023] Hematologic Malignancies 2 Mins Read207 John F. Seymour, MBBS, Ph.D., FRACP, a clinical haematologist and the Director of the Haematology Department at Peter MacCallum Cancer…
The Potential of Next Generation BTK Inhibitors in CLL / SLL Chronic Lymphocytic Leukemia 1 Min Read5 Emerging BTK inhibitors are positioned to change the landscape and impact your chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) treatment…
